During the third quarter, two prominent institutional investors significantly adjusted their positions in UnitedHealth Group. GDS Wealth Management reduced its holdings by 10.7%, disposing of 5,297 shares to end the period with 44,252 shares valued at $15.28 million. In the same quarter, Cullen Frost Bankers trimmed its position by 27.1%, selling 29,527 shares and holding 79,459 shares worth $27.44 million at quarter-end. Together, these transactions underscore cautious repositioning by major asset managers, even as overall institutional ownership remains near 88% of outstanding shares.

UnitedHealth Group reported third-quarter revenue of $113.16 billion, a 12.2% year-over-year increase, narrowly missing consensus estimates by $30 million. Adjusted earnings per share stood at $2.92, beating forecasts by $0.05 and reflecting resilient operating performance. The company maintained a net profit margin of 4.04% and a return on equity of 19.23%. Cash flow remained robust, supporting a quarterly dividend of $2.21 per share, equivalent to an annualized yield of 2.5%. The results set the stage for management’s full-year EPS guidance of approximately $29.54.

In the past month, research firms have updated their outlooks on UnitedHealth Group, with price objectives ranging from $409 to $430. Jefferies raised its target to $409 and reiterated a buy rating, while UBS lifted its objective to $430 following optimistic Medicare Advantage enrollment projections. Goldman Sachs initiated coverage with a $406 target and buy recommendation. Conversely, Piper Sandler trimmed its target slightly to $417, maintaining an overweight stance. Among 29 covered analysts, one assigned a Strong Buy, 17 a Buy, nine a Hold and two a Sell, yielding a consensus “Moderate Buy” opinion.

UnitedHealth Group’s adjusted debt-to-equity ratio stands at 0.71, and its quick ratio is 0.82, reflecting conservative leverage and ample liquidity. However, executives face heightened regulatory scrutiny after congressional hearings on affordability, and the company announced rebates on 2026 individual plan profits—actions that may pressure near-term margins. Analysts caution that rising medical cost ratios could temper fourth-quarter results, making the upcoming Medicare Advantage 2027 Advance Notice and cost-management updates critical catalysts for investor sentiment.